Strides Pharma Science Ltd (STAR)
·Next Day Close·-1.54%·₹1,184.2
Key EventTrading window closes for quarterly results
Strides Pharma Science Ltd (STAR)
·Next Day Close·-1.85%·₹1,202.7
Key EventStrides Pharma Science Limited published its FY26 Sustainability Report, aligning with GRI, SASB, and UNGC standards to detail ESG progress and future targets.
ImpactStrides demonstrates strong ESG integration with measurable climate targets, robust governance, and community impact, reducing risks while enhancing long-term value creation for shareholders through sustainable operations and stakeholder engagement.Sign up to read impact
Strides Pharma Science Ltd (STAR)
·Next Day Close·-2.83%·₹1,152.5
Key EventUSFDA completes inspection at Alathur facility, issues Form 483
ImpactInvestors should monitor how quickly the company resolves the observations and any subsequent regulatory updates.Sign up to read impact
Strides Pharma Science Limited (STAR)
·Next Day Close·+3.66%·₹992.05
Key EventStrides Pharma Science receives USFDA EIR for Bengaluru facility
ImpactThe regulatory clearance enhances investor confidence in Strides' manufacturing credibility and global market access.Sign up to read impact
Strides Pharma Science Limited (STAR)
·Next Day Close·+1.21%·₹957
Key EventAll resolutions passed at the 35th AGM with near-unanimous shareholder approval
ImpactShareholders approved dividend and director re-appointments, signaling confidence in company stability and governance.Sign up to read impact
Strides Pharma Science Limited (STAR)
·Next Day Close·+0.44%·₹1,027.8
Key EventStrides Pharma reported Q1 FY27 revenue of ₹12,654 crores, up 13% YoY, with EBITDA at ₹2,298 crores and PAT at ₹1,231 crores.
ImpactStrides delivered solid YoY growth in revenue and EBITDA despite cost pressures, improved net debt metrics, and plans for new product launches to drive future growth.Sign up to read impact
Strides Pharma Science Limited (STAR)
·Next Day Close·+0.44%·₹1,027.8
Key EventStrides Pharma Science announced Q1FY27 results with 13% YoY revenue growth to ₹12,654m.
ImpactShareholders see strong top-line growth and margin resilience despite external cost pressures, with a notable one-time gain boosting reported profits and a strategic stake sale unlocking value.Sign up to read impact
Strides Pharma Science Limited (STAR)
·Next Day Close·+0.44%·₹1,027.8
Key EventBoard approved Q3 FY2026 consolidated results with dividend proposal
ImpactThe company proposed a dividend of Rs. 5 per share pending shareholder approval, signaling confidence in cash flow despite revenue decline.Sign up to read impact
Strides Pharma Science Limited (STAR)
·Next Day Close·+2.45%·₹1,044
Key EventEarnings call scheduled for Q1 FY2026 results
ImpactThe call will provide insights into the company's quarterly performance and future outlook.Sign up to read impact
Strides Pharma Science Limited (STAR)
·Next Day Close·-1.2%·₹1,040.5
Key EventStrides Pharma Science Limited filed its BRSR report for FY25-26 on July 21, 2026, per SEBI LODR regulations.
ImpactThe BRSR confirms Strides' structured ESG integration with verified environmental metrics and community impact, but investors should assess long-term resilience against geopolitical and regulatory ESG risks.Sign up to read impact